2024 ICD-10-CM Diagnosis Code D07.0
Carcinoma in situ of endometrium
- ICD-10-CM Code:
- D07.0
- ICD-10 Code for:
- Carcinoma in situ of endometrium
- Is Billable?
- Yes - Valid for Submission
- Chronic Condition Indicator: [1]
- Chronic
- Code Navigator:
D07.0 is a billable diagnosis code used to specify a medical diagnosis of carcinoma in situ of endometrium. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024.
This code is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.
The following anatomical sites found in the Table of Neoplasms reference this diagnosis code given the correct histological behavior: Neoplasm, neoplastic corpus uteri ; Neoplasm, neoplastic corpus uteri isthmus ; Neoplasm, neoplastic endometrium (gland) (stroma) ; Neoplasm, neoplastic fetal membrane ; Neoplasm, neoplastic fundus uterus ; Neoplasm, neoplastic isthmus uteri ; Neoplasm, neoplastic myometrium ; etc
Approximate Synonyms
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Carcinoma in situ of body of uterus
- Carcinoma in situ of endometrium
- Carcinoma in situ of isthmus of uterus
- Carcinoma in situ of myometrium
- Carcinoma in situ of placenta
- Carcinoma in situ of uterus
- Neoplasm of isthmus of uterus
- Neoplasm of placenta
Clinical Classification
Clinical Category is Female reproductive system cancers - endometrium
- CCSR Category Code: NEO035
- Inpatient Default CCSR: Y - Yes, default inpatient assignment for principal diagnosis or first-listed diagnosis.
- Outpatient Default CCSR: Y - Yes, default outpatient assignment for principal diagnosis or first-listed diagnosis.
Clinical Information
Myometrium
the smooth muscle coat of the uterus, which forms the main mass of the organ.Abruptio Placentae
premature separation of the normally implanted placenta from the uterus. signs of varying degree of severity include uterine bleeding, uterine muscle hypertonia, and fetal distress or fetal death.Annexin A3
a protein of the annexin family that catalyzes the conversion of 1-d-inositol 1,2-cyclic phosphate and water to 1-d-myo-inositol 1-phosphate.Annexin A4
protein of the annexin family originally isolated from the electric organ of the electric ray torpedo marmorata. it has been found in a wide range of mammalian tissue where it is localized to the apical membrane of polarized epithelial cells.Annexin A5
a protein of the annexin family isolated from human placenta and other tissues. it inhibits cytosolic phospholipase a2, and displays anticoagulant activity.Cadherins
calcium-dependent cell adhesion proteins. they are important in the formation of adherens junctions between cells. cadherins are classified by their distinct immunological and tissue specificities, either by letters (e- for epithelial, n- for neural, and p- for placental cadherins) or by numbers (cadherin-12 or n-cadherin 2 for brain-cadherin). cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.Chorionic Villi
threadlike vascular projections of the chorion. chorionic villi may be free or embedded within the decidua forming the site for exchange of substances between fetal and maternal blood (placenta).Cord Blood Stem Cell Transplantation
transplantation of stem cells collected from the fetal blood remaining in the umbilical cord and the placenta after delivery. included are the hematopoietic stem cells.Eutheria
mammals which nourish their young in utero by means of a complex placenta, and give birth to their young alive. they include primates; carnivora, whales; ruminants; bats; and rodents.Folate Receptor 2
a subtype of gpi-anchored folate receptors that is expressed in placenta and hematopoietic cells.Ichthyosis, X-Linked
chronic form of ichthyosis that is inherited as a sex-linked recessive trait carried on the x-chromosome and transmitted to the male offspring. it is characterized by severe scaling, especially on the extremities, and is associated with steroid sulfatase deficiency.Perilipin-3
a perilipin that localizes to lipid droplets; cytoplasm; endosomes; and plasma membrane, especially in macrophages. it functions as a transporter of free fatty acids to lipid droplets to promote their biogenesis and growth. it is also required for the transport of the mannose-6-phosphate receptor from endosomes to the trans-golgi network. its structure consists of four helix bundles that interact with the hydrophobic lipid droplet surface.Placenta
a highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. it includes a fetal portion (chorionic villi) derived from trophoblasts and a maternal portion (decidua) derived from the uterine endometrium. the placenta produces an array of steroid, protein and peptide hormones (placental hormones).Placenta Accreta
abnormal placentation in which all or parts of the placenta are attached directly to the myometrium due to a complete or partial absence of decidua. it is associated with postpartum hemorrhage because of the failure of placental separation.Placenta Diseases
pathological processes or abnormal functions of the placenta.Placenta Growth Factor
an angiogenic protein belonging to the vascular endothelial growth factor family of growth factors originally isolated and cloned from human placental cdna library. there are four isoforms of plgf 1-4 which result from alternative splicing. placenta growth factor is secreted as a glycosylated homodimer which acts as a mitogen for endothelial cells, and its expression is markedly upregulated during hypoxia and in tissue inflammation and cancer.Placenta Previa
abnormal placentation in which the placenta implants in the lower segment of the uterus (the zone of dilation) and may cover part or all of the opening of the cervix. it is often associated with serious antepartum bleeding and premature labor.Placenta, Retained
a placenta that fails to be expelled after birth of the fetus. a placenta is retained when the uterus fails to contract after the delivery of its content, or when the placenta is abnormally attached to the myometrium.Placental Circulation
the circulation of blood, of both the mother and the fetus, through the placenta.Placental Extracts
extracts prepared from placental tissue; they may contain specific but uncharacterized factors or proteins with specific activities.Placental Function Tests
methods used for the assessment of placental function.Placental Hormones
hormones produced by the placenta include chorionic gonadotropin, and placental lactogen as well as steroids (estrogens; progesterone), and neuropeptide hormones similar to those found in the hypothalamus (hypothalamic hormones).Placental Insufficiency
failure of the placenta to deliver an adequate supply of nutrients and oxygen to the fetus.Placental Lactogen
a polypeptide hormone of approximately 25 kda that is produced by the syncytiotrophoblasts of the placenta, also known as chorionic somatomammotropin. it has both growth hormone and prolactin activities on growth, lactation, and luteal steroid production. in women, placental lactogen secretion begins soon after implantation and increases to 1 g or more a day in late pregnancy. placental lactogen is also an insulin antagonist.Placentation
the development of the placenta, a highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products between mother and fetus. the process begins at fertilization, through the development of cytotrophoblasts and syncytiotrophoblasts, the formation of chorionic villi, to the progressive increase in blood vessels to support the growing fetus.Plasminogen Inactivators
important modulators of the activity of plasminogen activators. the inhibitors belong to the serpin family of proteins and inhibit both the tissue-type and urokinase-type plasminogen activators.Pregnancy Proteins
proteins produced by organs of the mother or the placenta during pregnancy. these proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.)Pregnancy Trimester, First
the beginning third of a human pregnancy, from the first day of the last normal menstrual period (menstruation) through the completion of 14 weeks (98 days) of gestation.S100 Calcium-Binding Protein A4
an s100 protein characterized by four helix bundles that form n- and c-terminal ef hand motifs. it functions as a homodimer and interacts with both intracellular and extracellular signaling proteins. aberrant s100a4 activity is associated with neoplasm metastasis; fibrosis; and rheumatoid arthritis.Trophoblastic Tumor, Placental Site
an uncommon variant of choriocarcinoma. it is composed almost entirely of mononuclear cytotrophoblasts (trophoblasts). because its secretion of hcg (chorionic gonadotropin) is low, a large tumor may develop before the hcg can be detected.Umbilical Cord Clamping
method of placing clamps on the umbilical cord before cutting after birth.
Code Edits
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:
- Diagnoses for females only - The Medicare Code Editor detects inconsistencies between a patient’s sex and any diagnosis on the patient’s record, these edits apply to FEMALES only .
Convert D07.0 to ICD-9-CM
- ICD-9-CM Code: 233.2 - Ca in situ uterus NEC
Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.
Table of Neoplasms
This code is referenced in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.
Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.
| Neoplasm, neoplastic | Malignant Primary |
Malignant Secondary |
CaInSitu | Benign | Uncertain Behavior |
Unspecified Behavior |
|---|---|---|---|---|---|---|
| »Neoplasm, neoplastic »corpus »uteri | C54.9 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »corpus »uteri »isthmus | C54.0 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »endometrium (gland) (stroma) | C54.1 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »fetal membrane | C58 | C79.82 | D07.0 | D26.7 | D39.2 | D49.59 |
| »Neoplasm, neoplastic »fundus »uterus | C54.3 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »isthmus uteri | C54.0 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »myometrium | C54.2 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »placenta | C58 | C79.82 | D07.0 | D26.7 | D39.2 | D49.59 |
| »Neoplasm, neoplastic »stroma, endometrial | C54.1 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »uterus, uteri, uterine | C55 | C79.82 | D07.0 | D26.9 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »uterus, uteri, uterine »body | C54.9 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »uterus, uteri, uterine »cornu | C54.9 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »uterus, uteri, uterine »corpus | C54.9 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »uterus, uteri, uterine »endometrium | C54.1 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »uterus, uteri, uterine »fundus | C54.3 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »uterus, uteri, uterine »isthmus | C54.0 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »uterus, uteri, uterine »lower segment | C54.0 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
| »Neoplasm, neoplastic »uterus, uteri, uterine »myometrium | C54.2 | C79.82 | D07.0 | D26.1 | D39.0 | D49.59 |
Patient Education
Uterine Cancer
The uterus, or womb, is the place where a baby grows when a women is pregnant. There are different types of uterine cancer. The most common type starts in the endometrium, the lining of the uterus. This type is also called endometrial cancer.
The symptoms of uterine cancer include:
- Abnormal vaginal bleeding or discharge
- Trouble urinating
- Pelvic pain
- Pain during intercourse
Uterine cancer usually happens after menopause. It is more common in women who have obesity. You also have a higher risk if you took estrogen-only hormone replacement therapy (menopausal hormone therapy) for many years.
Tests to find uterine cancer include a pelvic exam, imaging tests, and a biopsy. The most common treatment is a hysterectomy, which is surgery to remove the uterus. Sometimes the surgery also removes the ovaries and fallopian tubes. Other treatments include hormone therapy, radiation therapy, and chemotherapy. Some women get more than one type of treatment.
NIH: National Cancer Institute
[Learn More in MedlinePlus]
Code History
- FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
- FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
- FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
- FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.
Footnotes
[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:
- The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
- The condition places limitations on self-care, independent living, and social interactions.